Athena Athena

X
[{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"PENAO Pty Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"Fermenta Biotech Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fermenta Biotech Licenses Its Proprietary Enzymatic Technology for Manufacturing Molnupiravir to Aurigene Pharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GARDP, Dr. Reddy\u2019s and Aurigene Pharmaceutical Services Limited Sign MOU for Antibiotic Access Through Collaborative Model","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Aurigene Pharmaceutical Services

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Fermenta Biotech will exclusively license its biocatalytic technology for synthesis of Molnupiravir (Molflu) and supply its enzyme Candida Antarctica B Lipase (CAL B) to Aurigene. Molnupiravir API manufactured by Aurigene will be utilised by Dr Reddy’s for its formulation.

            Lead Product(s): Molnupiravir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Molflu

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Fermenta Biotech Limited

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 21, 2022

            Aurigene company banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier

            Details:

            This next-generation adenine nucleotide translocase (ANT) inhibitor, PENAO, was shown to be safe and well-tolerated in a phase I clinical trial conducted in Australia where encouraging efficacy data was observed.

            Lead Product(s): PENAO,Sirolimus

            Therapeutic Area: Oncology Product Name: PENAO

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: PENAO Pty Ltd

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 18, 2021

            Aurigene company banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier

            Details:

            Through this MOU, the parties will seek to collaborate on efforts to determine market potential for zoliflodacin, therapeutic value to patients and explore possibilities to enter into future manufacturing and supply agreements.

            Lead Product(s): Zoliflodacin,Ceftriaxone,Azithromycin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: The Global Antibiotic Research and Development Partnership

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement December 17, 2020

            Aurigene company banner

            Biotechgate Digital

            Not Confirmed

            envelop Contact Supplier
            Post Enquiry
            POST ENQUIRY